Cybin announces additional U.S. patent granted for CYB003 to treat MDD

Cybin announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder or MDD. The patent, which is expected to provide exclusivity until at least 2041, includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program, CYB003. “As we continue to advance CYB003, our deuterated psilocybin analog program for the adjunctive treatment of MDD, further protecting our intellectual property through patent protection is an important achievement,” said Doug Drysdale, Chief Executive Officer of Cybin. “The strength of our patents supporting CYB003 underscore our commitment to developing innovative, next-generation, commercially scalable therapeutics to address the significant unmet medical need in MDD. With our robust patent portfolio, and the recent Breakthrough Therapy Designation by the U.S. Food and Drug Administration, we are encouraged by our regulatory pathway for CYB003 and are positioned to move quickly to progress the program,” concluded Drysdale.